There have been no new FDA-approved pharmacological treatment options for plantar fasciitis. The current treatments for the disorder either provide only temporary relief or are quite invasive. In the hope to provide a potential treatment option for the millions of people who seek relief from this debilitating foot pain, DaxibotulinumtoxinA for Injection was evaluated in a clinical trial for the management of plantar fasciitis. To learn more about the Phase 2 clinical trial, click here.
Beyond plantar fasciitis, Revance is continuing to study DaxibotulinumtoxinA for Injection in other important therapeutic indications with a current focus in muscle movement disorders.
DaxibotulinumtoxinA for Injection has delivered highly positive Phase 3 results, including strong duration of effect, demonstrating a median duration of 24 weeks in the treatment of glabellar lines and cervical dystonia. Additionally, Revance plans to share Phase 2 trial results for upper limb spasticity in first quarter 2021.